|
|
||||||||
University of Colorado Health Sciences Center and Veterans Administration Medical Center, Denver, Colorado
Correspondence: For reprints contact: Alan R. Fritzberg, PhD, Department of Radiology, A034, U. of Colorado Health Sciences Center, 4200 E. 9th Ave., Denver, CO 80262.
ABSTRACT
A new technetium-chelating agent based on amide and mercaptide donor groups, N,N'-bis(mercaptoacetyl)-2,3-diaminopropanoate, was synthesized as an analog of previously described N,N'-bis(mercaptoacetyl)ethylenediamine (DADS). Complexation of Tc-99m with the new chelating group resulted in two components that were separable by high-performance liquid chromatography. The component that eluted first demonstrated high specificity for renal excretion, with over 90% In the urine of rabbits at 35 min, 87% in the urine of mice at 2 hr, and 1.6% or less in the intestines of mice. Excretion was rapid, with the first component equaling or exceeding [131I]o-iodohippurate in the urine of rabbits at all times. The second or latter component demonstrated comparable specificity but slightly slower renal excretion kinetics. Clinical trials with the first component are probably warranted.
This article has been cited by other articles:
![]() |
M. Lipowska, H. He, E. Malveaux, X. Xu, L. G. Marzilli, and A. Taylor First Evaluation of a 99mTc-Tricarbonyl Complex, 99mTc(CO)3(LAN), as a New Renal Radiopharmaceutical in Humans J. Nucl. Med., June 1, 2006; 47(6): 1032 - 1040. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Taylor, M. Lipowska, L. Hansen, E. Malveaux, and L. G. Marzilli 99mTc-MAEC Complexes: New Renal Radiopharmaceuticals Combining Characteristics of 99mTc-MAG3 and 99mTc-EC J. Nucl. Med., May 1, 2004; 45(5): 885 - 891. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |